USFDA approves Regeneron's ultra-rare blood disease drug

Veopoz - the first treatment to be approved by the U.S. Food and Drug Administration for the life-threatening disease - will be sold in the U.S. at a list price of $34,615.38 per single-use vial, the company told Reuters in an emailed response.